近两年来最大生物技术并购!强生百亿收购Intra-Cellular,后者盘前飙升近38%

华尔街见闻
13 Jan

强生收购intra-cellular,将目光瞄准中枢神经系统疾病市场。13日,强生公司以146亿美元收购Intra-Cellular Therapies,以增强其在神经系统疾病治疗市场的地位。这是自2023年以来最大的生物技术并购交易,也是2024年以来首个超过100亿美元的生物医药并购。Intra-Cellular股价在盘前交易中飙升近38%,过去12个月,该公司股价已上涨约40%,市值约为...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10